Skip to content

Multiomics Study of Biological Behavior of Lymph Node Metastasis in Papillary Thyroid Carcinoma

Multiomics Study of Biological Behavior of Lymph Node Metastasis in Papillary Thyroid Carcinoma

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06725628
Enrollment
2000
Registered
2024-12-10
Start date
2024-12-01
Completion date
2024-12-01
Last updated
2024-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymph Node Cancer Metastatic, Papillary Thyroid Carcinoma

Brief summary

Establish a predictive model for assessing neck lymph node metastasis of papillary thyroid carcinoma based on metabolomics, proteomics, and imaging omics data, exploring an ideal protocal for the precise diagnosis and treatment of papillary thyroid carcinoma.

Detailed description

This study is a multicenter, observational cohort study aimed at assessing the accuracy and effectiveness of the ThyMPR-CLNM multi-omics model in predicting CLNM in patients diagnosed with stage T1 PTC. The design incorporates the following critical components: The study enrolled 2000 patients diagnosed with stage T1 PTC from Hangzhou Traditional Chinese Medical Hospital, affiliated with Zhejiang Chinese Medical University, between Dec.2024 and Dec.2026. Fresh frozen tumor tissue, serum samples, and preoperative ultrasound images were collected from participants. These samples were utilized for comprehensive multi-omics analyses, including metabolomic and proteomic profiling, as well as ultrasound radiomic feature extraction. To minimize selection bias and balance covariates, propensity score matching was performed in two rounds, establishing a discovery set and a validation set with matched groups based on the propensity scores calculated through logistic regression. This ensured comparable groups for subsequent analyses. The study involved analyzing the collected samples through advanced techniques such as liquid chromatography-mass spectrometry (LC-MS) for metabolomic and proteomic analyses, and Pyradiomics for extracting radiomics features from ultrasound images. Differentially expressed metabolites, proteins, and radiomic features were identified and integrated for the development of the ThyMPR-CLNM prediction model. The Least Absolute Shrinkage and Selection Operator (LASSO) regression technique was utilized to construct the ThyMPR-CLNM model based on identified features from the multi-omics analyses. The model's performance was subsequently validated using an independent dataset. Statistical evaluations were performed using R software to determine the model's accuracy, sensitivity, specificity, and AUC values. Comparisons with conventional diagnostic methods were conducted to highlight the ThyMPR-CLNM model's advantages.

Interventions

DIAGNOSTIC_TESTThy_CLNM_multi_omics

Surgery

Sponsors

Tianhan Zhou
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Pathological confirmation of PTC. 2. Patients who underwent primary surgery accompanied by central neck lymph node dissection. 3. Tumors measuring less than 2 cm in diameter. 4. Postoperative pathological reports including detailed information on the number of lymph nodes dissected and the number of metastatic lymph nodes. 5. Availability of comprehensive preoperative thyroid ultrasound images for analysis.

Exclusion criteria

1. Postoperative pathological diagnosis indicating sub-types of PTC. 2. Tumor invasion into adjacent anatomic structures such as the sternothyroid muscle, surrounding soft tissues, trachea, esophagus, or laryngeal nerve. 3. History of neck trauma, previous tumor surgery, or adjuvant chemoradiotherapy. 4. Fewer than three lymph nodes dissected during surgery. 5. Concurrent acute inflammatory conditions or other hematologic disorders.

Design outcomes

Primary

MeasureTime frameDescription
Lymph node metastasis statusRecord lymph node metastasis status until the end of the surgery, followed by a one-year follow-up until the conclusion of the study.Patients with thyroid cancer undergo thyroid cancer radical surgery according to the guidelines, with pathological results including the number of lymph node metastases and metastasis status, based on the final pathological diagnosis.

Secondary

MeasureTime frameDescription
Surgical complications and postoperative recurrenceRecord surgical complications until the end of the surgery, followed by a one-year follow-up until the conclusion of the study.Hemorrhage,Infection,Recurrent laryngeal nerve injury,Hypothyroidism,Other related surgical complications and Recurrence status

Contacts

Primary ContactTianhan Zhou
201911122511374@zcmu.edu.cn8615556960687

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 14, 2026